Considerations for widespread implementation of blood‐based biomarkers of Alzheimer's disease.

Diagnosing Alzheimer's disease (AD) poses significant challenges to health care, often resulting in delayed or inadequate patient care. The clinical integration of blood‐based biomarkers (BBMs) for AD holds promise in enabling early detection of pathology and timely intervention. However, several critical considerations, such as the lack of consistent guidelines for assessing cognition, limited understanding of BBM test characteristics, insufficient evidence on BBM performance across diverse populations, and the ethical management of test results, must be addressed for widespread clinical implementation of BBMs in the United States. The Global CEO Initiative on Alzheimer's Disease BBM Workgroup convened to address these challenges and provide recommendations that underscore the importance of evidence‐based guidelines, improved training for health‐care professionals, patient empowerment through informed decision making, and the necessity of community‐based studies to understand BBM performance in real‐world populations. Multi‐stakeholder engagement is essential to implement these recommendations and ensure credible guidance and education are accessible to all stakeholders. [ABSTRACT FROM AUTHOR]